Last reviewed · How we verify

NCT02121054

Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease

Completed Last updated 20 March 2023
What this trial tests

trial in Cardiovascular Diseases in 1,527 participants. Completed in 29 October 2020.

Timeline
19 October 2013
Primary endpoint
29 October 2020
29 October 2020

Quick facts

Lead sponsorYoung-Hak Kim, MD, PhD
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,527
Start date19 October 2013
Primary completion29 October 2020
Estimated completion29 October 2020
Sites1 location across South Korea

Conditions studied

Sponsor

Young-Hak Kim, MD, PhD

Who can join

20 and older, any sex, with Cardiovascular Diseases or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the prognosis of patients with resistance to antiplatelet agent and develop tailored treatment model for patients with coronary artery disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Young-Hak Kim, MD, PhD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02121054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing